Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elan/Biogen Idec's Tysabri, Formerly Antegren, Approved For MS Based On One-Year Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Monoclonal antibody's label includes studies as monotherapy and as add-on in patients previously treated with Avonex. Two-year results are expected in the first half of 2005.

You may also be interested in...



Accelerated Approval Great For “Me-Too” Products, FDA Says

CDER’s Bob Temple explains how competitors could actually help speed up a drug approval but also hold a product to a higher standard.

Durability Questions Mean Northera Should Be Limited To Short-Term Use, Panel Says

The durability of treatment effect for Chelsea’s NOH drug is an issue for a post-marketing study to answer, FDA’s Cardiovascular and Renal Drugs Advisory Committee said in recommending approval on a 16-1 vote.

Genzyme/Bayer Report Positive Top-Line Phase II MS Data For Campath

Clinical hold on the Phase II trial was lifted “within the last six months” and dosing completed, Genzyme’s Enyedy says.

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel